[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335320-105":59,"doc-detail-335320-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinicopathological-characteristics-treatment-patterns-and-outcomes-in-patients-with-her2-positive-breast-cancer-based-on-hormone-receptor-status-a-retrospective-study","Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status - A retrospective study","","Different hormone receptor (HR) expression patterns in HER2-positive breast cancer carry distinct biological and therapeutic implications, yet the separation of HR-positive/HER2-positive (HR+/HER2+) versus HR-negative/HER2-positive (HR-/HER2+) subtypes remains insufficiently clarified. A retrospective analysis examined 828 HER2-positive patients from 2012 to 2022, comparing baseline characteristics and estimating survival using chi-square tests and Kaplan-Meier methods. HR+/HER2+ showed favorable clinicopathological features, improved DFS and overall survival, and better outcomes with endocrine therapy and maintenance strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathological-characteristics-treatment-patterns-and-outcomes-in-patients-with-her2-positive-breast-cancer-based-on-hormone-receptor-status-a-retrospective-study/335320/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathological-characteristics-treatment-patterns-and-outcomes-in-patients-with-her2-positive-breast-cancer-based-on-hormone-receptor-status-a-retrospective-study/335320.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this study?","Question",{"text":112,"@type":113},"To clarify differences in clinicopathological characteristics, treatment patterns, and outcomes among HER2-positive breast cancer patients based on hormone receptor status (HR+/HER2+ vs HR-/HER2+).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many HER2-positive patients were analyzed, and what period did the study cover?",{"text":117,"@type":113},"The retrospective study included 828 HER2-positive breast cancer patients treated at the First Affiliated Hospital of Xi’an Jiaotong University from 2012 to 2022.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment-related findings were reported for HR+/HER2+ patients?",{"text":121,"@type":113},"HR+/HER2+ patients were less sensitive to neoadjuvant therapy, and in first-line treatment for advanced disease, endocrine therapy improved advanced overall survival and progression-free survival compared with not using endocrine therapy; maintenance endocrine therapy after HER2-targeted therapy and chemotherapy also showed benefits.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335320,1790194160,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Ran et al. BMC Cancer (2024) 24:1216 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12974-4](https://doi.org/10.1186/s12885-024-12974-4)  \nRESEARCH Open Access  \nClinicopathological characteristics, treatment  patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study  \nRan Ran 1,2, Shidi Zhao 1,2, Yan Zhou 1,2, Xinyue Hang 1,2, Hui Wang 1,2, Yuan Fan 1,2, Yusi Zhang 1,2, Yifan Qiao 1,2, Jin Yang 1,2* and Danfeng Dong 1,2*  \nAbstract  \nBackground Different hormone receptor (HR) expression patterns have significant biological and therapeutic implications in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the distinction between HR-positive /HER2-positive (HR+/HER2+) and HR-negative/HER2-positive (HR-/HER2+) subtypes remains unclear.  \nMethods This retrospective study analyzed 828 patients with HER2-positive breast cancer at the First Affiliated Hospital of Xi’an Jiaotong University from 2012 to 2022. Baseline characteristics were compared by chi-square test. Survival outcomes were estimated by Kaplan-Meier method.  \nResults In total, 56 . 3%(n = 466) had HR-positive and 43 . 7%(n = 362) had HR-negative disease. Comparatively, HR+/ HER2 + breast cancers presented favorable clinicopathological features. At a median follow-up of 49 months, 199 disease-free survival (DFS) events and 99 deaths were observed. HR+/HER2 + patients had significantly better survival outcomes than HR-/HER2 + patients. HR-positive status was an independent protective factor for overall survival (OS)[P = 0 . 032; hazard ratio, 0 . 61; 95% confidence interval (CI), 0 .39–0. 96] and DFS (P = 0 . 001; hazard ratio, 0 . 61; 95% CI, 0.46–0. 81) . HR+/HER2 + patients were significantly less sensitive to neoadjuvant therapy than HR-/HER2 + patients. In the first-line treatment for HR+/HER2 +advanced breast cancer, receiving endocrine therapy significantly improved advanced-OS (P \u003C 0. 001; hazard ratio, 0 . 33; 95% CI, 0 .18–0. 59) and progression-free survival (PFS) (P \u003C 0. 001; hazard ratio, 0 . 38; 95% CI, 0 .25–0. 58) compared with not receiving endocrine therapy. Moreover, maintenance endocrine therapy after HER2-targeted therapy and chemotherapy is associated with significant advanced-OS and PFS benefits compared with no maintenance endocrine therapy (advanced-OS: P \u003C 0. 001; hazard ratio, 0 . 05; 95% CI, 0 .03–0. 12; PFS: P \u003C 0. 001; hazard ratio, 0 . 35; 95% CI, 0 .21–0. 57) .  \n*Correspondence: Jin Yang [yangjin@mail.xjtu.edu.cn](yangjin@mail.xjtu.edu.cn)[ ](yangjin@mail.xjtu.edu.cn)Danfeng Dong [qiwudanfeng@163.com](qiwudanfeng@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nRan et al. BMC Cancer (2024) 24:1216 Page 2 of 17  \nConclusions This study reveals the high heterogeneity of HER2-positive breast cancer related to HR status incli","cbCaigAOe0TPTBbs","https://ap.wps.com/l/cbCaigAOe0TPTBbs","pdf",2188525,17,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To clarify differences in clinicopathological characteristics, treatment patterns, and outcomes among HER2-positive breast cancer patients based on hormone receptor status (HR+/HER2+ vs HR-/HER2+).\"},{\"question\":\"How many HER2-positive patients were analyzed, and what period did the study cover?\",\"answer\":\"The retrospective study included 828 HER2-positive breast cancer patients treated at the First Affiliated Hospital of Xi’an Jiaotong University from 2012 to 2022.\"},{\"question\":\"What treatment-related findings were reported for HR+/HER2+ patients?\",\"answer\":\"HR+/HER2+ patients were less sensitive to neoadjuvant therapy, and in first-line treatment for advanced disease, endocrine therapy improved advanced overall survival and progression-free survival compared with not using endocrine therapy; maintenance endocrine therapy after HER2-targeted therapy and chemotherapy also showed benefits.\"}]","Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status - A retrospective study | PDF",1790010518,43]